Joshua Roth, PhD, assistant member, Fred Hutchinson Cancer Research Center, discusses the design of a novel risk-prediction algorithm in the context of screening patients for lung cancer.
Joshua Roth, PhD
Advertisement
Articles by Joshua Roth, PhD
Joshua Roth, PhD, assistant member, Fred Hutchinson Cancer Research Center, discusses the rationale behind the development of a novel risk-prediction algorithm in the context of screening patients for lung cancer. He discussed this during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.
Advertisement
Latest Updated Articles
The Design Behind the Development of a Novel-Risk Prediction Model in Lung Cancer ScreeningPublished: June 6th 2017 | Updated:
Dr. Roth on the Rationale Behind a Novel Risk-Prediction Model in Lung Cancer ScreeningPublished: December 5th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5